Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model
- 20 November 2003
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 59 (6), 734-742
- https://doi.org/10.1046/j.1365-2265.2003.01915.x
Abstract
Background Introduction of genes encoding immuno‐stimulatory cytokine(s) into cancer cells is well known to enhance anti‐tumour immunity. aim The present studies were designed to evaluate the therapeutic efficacy of retroviral‐ and adenoviral‐mediated delivery of IL‐12 and/or granulocyte macrophage colony‐stimulating factor (GM–CSF) genes for thyroid cancer in an immuno‐competent rat model. methods A rat thyroid cancer cell line FRTL‐Tc syngeneic to Fisher rat was used. results Expression of these exogenous cytokines did not affect in vitro cell growth. Subcutaneous injection of FRTL‐Tc cells retrovirally transduced with IL‐12 or GM–CSF genes formed significantly smaller tumours than that of the parental cells, but had little effect on growth of distant tumours, suggesting no vaccine effect. Similarly, injection of the cells infected with adenovirus expressing IL‐12 or GM–CSF (AdIL‐12 or AdGM–CSF) almost completely abolished tumourigenicity and injection of AdGM–CSF into pre‐established tumours significantly inhibited growth of the tumours injected; neither, however, showed a systemic vaccine affect. On the other hand, injection of AdIL‐12 into the pre‐established tumours significantly inhibited growth of not only the tumours injected but also distant tumours, indicating induction of systemic anti‐tumour immunity. Serum IL‐12 was detectable only in this approach. There was neither a synergistic or additive effect of these two cytokines. conclusions Our data demonstrate in a rat thyroid cancer model that only injection of AdIL‐12 into the pre‐established tumours elicited systemic anti‐tumour immunity, but injection of AdGM–CSF or injection of the cells expressing IL‐12 or GM–CSF elicited only local effect, indicating that in situ delivery of IL‐12 gene with adenovirus appears most efficacious but may still require adjuvant modalities to enhance the anti‐tumour effect.Keywords
This publication has 32 references indexed in Scilit:
- Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinomaCancer Gene Therapy, 2001
- Efficient Gene Delivery into Dendritic Cells by Fiber-Mutant Adenovirus VectorsBiochemical and Biophysical Research Communications, 2001
- Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP systemCancer Gene Therapy, 2001
- Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma modelClinical Endocrinology, 2000
- Effective repeat administration with adenovirus vectors to the muscleGene Therapy, 2000
- In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.JCI Insight, 1998
- Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus disseminationGene Therapy, 1997
- Genetic Immunotherapy of Established Tumors with Adenovirus-Murine Granulocyte-Macrophage Colony-Stimulating FactorHuman Gene Therapy, 1997
- IL-12: a key cytokine in immune regulationImmunology Today, 1996
- IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts. University of Pittsburgh, Pittsburgh, PennsylvaniaHuman Gene Therapy, 1995